Steve Carle is an experienced private equity and venture capital specialist and an Investment Director at Edge Investments.
Steve enjoyed a successful 20-year career with the UK’s two leading mid-market private equity companies before leaving in 2010 to take on more personal business opportunities and joined Edge in 2015.
Between 1991 and 1999, Steve worked in the Edinburgh and Cambridge offices of 3i Group plc where he invested in businesses as widely disparate as PPL Therapeutics (who famously cloned Dolly the Sheep), and Greenvale Produce the UK’s largest potato packing business. In 1999 he left 3i to join LDC, the private equity arm of Lloyds Banking Group. Between 1999 and 2010, when Steve left the company, LDC had grown to become the UK’s leading mid-market private equity investor. While at LDC, Steve was responsible for some of its most successful deals, including Penn Pharmaceuticals, Insys and Dennis Eagle. The transactions with which he was involved at LDC have already delivered near 100% capital gains.